Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study

Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study

Abstract Background Clinical studies demonstrate that ivacaftor (IVA) improves health-related quality of life (HRQoL) in patients aged ≥6 years with cystic fibrosis (CF). The real-world impact of IVA and standard of care (SOC) in groups of patients with G551D and F508del mutations, respectively, was...

Full description

Bibliographic Details
Main Authors: Scott C. Bell, Jochen G. Mainz, Gordon MacGregor, Susan Madge, Julie Macey, Moshe Fridman, Ellison D. Suthoff, Siva Narayanan, Nils Kinnman
Format: Article
Language:English
Published: BMC 2019-08-01
Series:BMC Pulmonary Medicine
Subjects:
Patient-reported outcomes
Work productivity
Ivacaftor
Cystic fibrosis
G551D-CFTR
Online Access:http://link.springer.com/article/10.1186/s12890-019-0887-6

Internet

http://link.springer.com/article/10.1186/s12890-019-0887-6

Similar Items